Author: upwork

Intomics contributes to new article: A new gene panel for colon cancer based on NGS data

Intomics is taking part in a publicly founded research project within colon cancer. The other project participants are the Technical University of Denmark, Vejle Hospital and the private company Exiqon. The role of Intomics is to analyze and interpret the anonymized NGS data stemming from colon tumors.

CEO of Intomics Thomas Skøt Jensen explains: ”The overall aim of the project is to identify genetic variations of colon tumors enabling better and more precise diagnosis. This again bear promise for optimized and individualized treatment-regiments with improved patient outcomes. Additionally, we expect that the specific project-developed algorithms can be applied more generally to similar challenges within other cancer diseases.”

Recently an article on the project was published. Read more here

Intomics selected as one of Denmarks fastest growing companies of 2017

Every year Danish business newspaper ‘Børsen’ selects the fastest growing companies of Denmark in what is denoted the ‘Gazelle’-awards. Companies are selected based on objective financial criterias, one of them being a  >100 % growth during the last 4 consecutive years as reported in the annual financial statements.

Thomas Skøt Jensen, CEO and co-founder was one of Intomics participants at the ‘Gazelle’-awardshow: ”Intomics has been growing rapidly the last four years. By maintaining a strong focus on delivering world class bioinformatics solutions to existing and new customers in the pharmaceutical industry we fully expect to continue our growth-journey in 2018 and beyond.”

Nature Methods reveals Intomics PPI network to be Best-in-class

Nature Methods publication reveals Intomics’ proprietary Protein-Protein Interaction Network, InBio MapTM, to be best-in-class in a benchmark study against five commonly used comparable resources.

Nov. 28th, Nature Methods published (online) a comparative study of leading Protein-Protein Interaction (PPI) Networks. The publication entitled ”A scored human protein-protein interaction network to catalyze genomic interpretation” finds Intomics’ InBio MapTM (entitled InWeb_IM in the publication) to have twice as much data as the second largest network and have 16% better ability to discover pathways.

”We are very proud of the conclusions in this publication. InBio MapTM was from the very beginning designed as a high-quality resource that could facilitate the next generation of biological discoveries and this comparative study confirms its potential.” says CEO of Intomics, Thomas Skot Jensen and continues ”In line with the findings in the publication, Intomics has applied the InBio MapTM extensively in our work for world-leading pharmaceutical companies and have found, that it can provide unique new insights into biology”.

Corresponding author, Kasper Lage, assistant professor of Surgery at Harvard Medical School, adds, “The rapidly declining cost of genome sequencing has far outpaced our ability to interpret the gene variants we identify in patients with undiagnosed diseases. By exploring interaction networks at the level of proteins and of the genes that may be causing a disease, clinicians may begin to see patterns of genetic data that would otherwise be difficult to discern, which we illustrate in the article for cancers and autism. As another example, around 30 genes appear to be involved in cardiomyopathies, but many individuals with the condition do not have mutations in any of those genes. By looking at interaction partners at the protein level of the 30 cardiomyopathy genes, we can start to identify new candidate genes based on the ‘cardiomyopathy network,’ potentially leading to new molecular insights into the disease. It is our hope that InWeb_IM can contribute to interpreting clinical exome sequencing data and play a part in enabling clinical action in patients with an unknown cause of disease.”

Intomics’ Scientific Director Rasmus Wernersson elaborates: “With InBio MapTM as a pivotal resource, we have helped pharmaceutical companies increase the outcome of target discovery efforts with 200 %. Additionally, we have developed personalized medicine approaches that, based on genetic data, could predict responding patients in clinical trials with 91 % accuracy, thus paving the way for tomorrow’s medicines. This is in perfect agreement with Intomics vision.”

The publication can be found online via this link.
For further information, please contact Intomics’ CEO, Thomas Skot Jensen, at Email:

Phone: +45 88 80 79 79